-
公开(公告)号：US10765706B2
公开(公告)日：2020-09-08
申请号：US15257315
申请日：2016-09-06
摘要： Blood brain barrier (BBB) permeabilizers, such as mannitol, can facilitate the entry of stem cells from the periphery to the stroke brain. It is unknown whether BBB permeation in the chronic stage of the disease still facilitates the entry of stem cells from the periphery to the injured brain. Evidence herein shows BBB permeation in the chronic stage of stroke assisted in the entry of stem cells from the periphery to the stroke brain. Stroke models treated with human umbilical cord stem cells (hUCBC) only (2 million viable cells), mannitol or a combination. Results revealed that hUCBC alone or combined with mannitol displayed significant behavioral and histological deficits compared to control animals, with the HUCBC-mannitol combined treatment showing improvements over hUCBC only treatments in brain cell survival in the peri-infarct area. BBB permeation in chronic stroke also lowers the effective stem cell dose necessary to improve functional outcomes.
-
公开(公告)号：US10130683B1
公开(公告)日：2018-11-20
申请号：US14823637
申请日：2015-08-11
摘要： A combined therapy of human umbilical cord blood cells (hUCB) and G-CSF at the acute stage of TBI was tested as a therapeutic for progressive secondary effects of chronic TBI. Rats were treated with saline carrier, or therapeutic in carrier as follows; G-CSF, hUCB, or hUCB and G-CSF, 7-days after TBI. Eight weeks later, behavioral testing was performed and brains harvested to analyze hippocampal cell loss, neuroinflammatory response, and neurogenesis. Results revealed that the monotherapies partially suppressed neuroinflammation and reduced hippocampal cell loss. However, combined therapy of hUCB and G-CSF robustly dampened neuroinflammation, while enhancing endogenous neurogenesis and reducing hippocampal cell loss. Vigorous and long-lasting recovery of motor function accompanied the combined therapy, which was either moderately or short-lived in the monotherapy conditions. These results suggest that combined treatment rather than monotherapy appears optimal for abrogating histophalogical and motor impairments in chronic TBI.
-
3.发明申请METHOD OF STEM CELL DELIVERY INTO THE BRAIN DURING CHRONIC DISEASE USING BLOOD BRAIN BARRIER PERMEABILIZERS 审中-公开使用血脑膜阻滞剂治疗慢性疾病的干细胞移植到脑中的方法公开(公告)号：US20170065643A1
公开(公告)日：2017-03-09
申请号：US15257315
申请日：2016-09-06
CPC分类号： A61K35/51 , A61K9/0019 , A61K47/26
摘要： Blood brain barrier (BBB) permeabilizers, such as mannitol, can facilitate the entry of stem cells from the periphery to the stroke brain. It is unknown whether BBB permeation in the chronic stage of the disease still facilitates the entry of stem cells from the periphery to the injured brain. Evidence herein shows BBB permeation in the chronic stage of stroke assisted in the entry of stem cells from the periphery to the stroke brain. Stroke models treated with human umbilical cord stem cells (hUCBC) only (2 million viable cells), mannitol or a combination. Results revealed that hUCBC alone or combined with mannitol displayed significant behavioral and histological deficits compared to control animals, with the HUCBC-mannitol combined treatment showing improvements over hUCBC only treatments in brain cell survival in the peri-infarct area. BBB permeation in chronic stroke also lowers the effective stem cell dose necessary to improve functional outcomes.
摘要翻译： 血脑屏障（BBB）渗透剂如甘露醇可以促进干细胞从外周进入脑卒中。 在慢性疾病阶段BBB渗透是否还有助于干细胞从外周进入受损脑。 本文的证据表明，BBB在慢性中风期的渗透有助于干细胞从外周进入脑卒中。 仅用人脐带干细胞（hUCBC）处理的中风模型（200万活细胞），甘露醇或组合。 结果显示，与对照动物相比，hUCBC单独或与甘露醇组合显示出显着的行为和组织学缺陷，HUCBC-甘露醇联合治疗显示出在脑梗死区域的脑细胞存活中仅用于hUCBC治疗的改善。 慢性脑卒中中的BBB渗透也降低了改善功能结果所需的有效干细胞剂量。
-
公开(公告)号：US10285935B2
公开(公告)日：2019-05-14
申请号：US15384808
申请日：2016-12-20
申请人： Svitlana Garbuzova-Davis , Cesario Venturina Borlongan , Harry Ronald van Loveren , Peter Richard Nelson
发明人： Svitlana Garbuzova-Davis , Cesario Venturina Borlongan , Harry Ronald van Loveren , Peter Richard Nelson
摘要： Most spinal cord therapies are administered systemically, with only a small portion of the therapeutic reaching the spinal cord. A novel method for delivering therapeutics directly to the spinal cord is provided. The method uses a dual balloon catheter to isolate the microvasculature around a region of the spinal cord. Once isolated, one or more therapeutics are delivered directly to the spinal cord blood supply. This allows for smaller, safer therapeutic dose to be utilized.
-
5.发明申请公开(公告)号：US20170173307A1
公开(公告)日：2017-06-22
申请号：US15384808
申请日：2016-12-20
申请人： Svitlana Garbuzova-Davis , Cesario Venturina Borlongan , Harry Ronald van Loveren , Peter Richard Nelson
发明人： Svitlana Garbuzova-Davis , Cesario Venturina Borlongan , Harry Ronald van Loveren , Peter Richard Nelson
IPC分类号： A61M25/10
CPC分类号： A61K9/0019 , A61M25/1011 , A61M2025/1052
摘要： Most spinal cord therapies are administered systemically, with only a small portion of the therapeutic reaching the spinal cord. A novel method for delivering therapeutics directly to the spinal cord is provided. The method uses a duel-balloon catheter to isolate the microvasculature around a region of the spinal cord. Once isolated, one or more therapeutics are delivered directly to the spinal cord blood supply. This allows for smaller, safer therapeutic does to be utilized.
-
公开(公告)号：US10357517B1
公开(公告)日：2019-07-23
申请号：US14974088
申请日：2015-12-18
IPC分类号： A61K48/00 , A01N63/00 , C12N5/00 , C12N5/079 , C12N5/0797 , C12N5/0793 , C12N5/074 , C12N5/0735 , C12N5/071 , C12N5/07 , C12N5/16 , A61K35/30 , A61K9/00 , G01N33/50 , C12Q1/6809 , C07K14/435
摘要： Provided herein is a method of diagnosing or prognosing an epilepsy or epilepsy-related disorder. Also provided herein is a method of treating an epilepsy or epilepsy-related disorder. Further provided are non-epileptic and epileptic neural stem cells and cell cultures.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.028 秒)